INTRODUCTION {#nep12958-sec-0005}
============

Cardiovascular (CV) disease is the most critical cause of mortality and morbidity in patients undergoing dialysis. The United States Renal Data System (USRDS) indicated that acute myocardial infarction (AMI) and congestive heart failure (CHF) have been recognized as the leading causes of death in elderly patients undergoing dialysis since 1999.[1](#nep12958-bib-0001){ref-type="ref"} In Taiwan, AMI has been the leading cause of hospitalization in patients with end‐stage renal disease (ESRD) since 2001.[2](#nep12958-bib-0002){ref-type="ref"} The incidence of acute coronary syndrome (ACS) in patients undergoing dialysis has been reported to be 1.78 per 100 person‐years in Taiwan and 10.2% within a 2.2‐year follow‐up in the United States, respectively.[3](#nep12958-bib-0003){ref-type="ref"}, [4](#nep12958-bib-0004){ref-type="ref"} Compared to the general population, the survivals of the patients with advanced chronic kidney disease after AMI were much shorter, with a mean survival period of only 22 months.[5](#nep12958-bib-0005){ref-type="ref"} The risk factors for AMI and ACS in ESRD include the male sex, old age, smoking, physical inactivity, hypertension (HTN), diabetes mellitus (DM), hyperlipidaemia (HL), and anaemia.[3](#nep12958-bib-0003){ref-type="ref"}, [5](#nep12958-bib-0005){ref-type="ref"} The mechanisms underlying incident ACS episodes included accelerated coronary calcification,[6](#nep12958-bib-0006){ref-type="ref"} platelet‐activation factors and thrombosis,[7](#nep12958-bib-0007){ref-type="ref"} and autonomic dysfunction.[8](#nep12958-bib-0008){ref-type="ref"}

Secondary hyperparathyroidism (SHPT) is prevalent in patients undergoing dialysis. Several studies have reported a close relationship between SHPT and the increased risk of CV events, including AMI, stroke, and CV death.[9](#nep12958-bib-0009){ref-type="ref"}, [10](#nep12958-bib-0010){ref-type="ref"} Only 22% of patients with severe SHPT who received medical therapy may achieve the ideal serum parathyroid hormone (PTH) level.[11](#nep12958-bib-0011){ref-type="ref"} In a multi‐centre randomized controlled trial, the investigators concluded, in dialysis patients with moderate to severe SHPT, treatment with calcimimetic failed to reduce the risk of CV events or death.[12](#nep12958-bib-0012){ref-type="ref"} Parathyroidectomy (PTX) is the main treatment for severe SHPT refractory to medical treatment. Conzo *et al*. reported that PTX may effectively reduce the PTH level and maintain appropriate levels up to 5 years.[13](#nep12958-bib-0013){ref-type="ref"} Previous studies have reported a reduced risk of major CV events, including stroke, AMI, peripheral arterial disease and mortality in patients with SHPT who underwent PTX.[14](#nep12958-bib-0014){ref-type="ref"}, [15](#nep12958-bib-0015){ref-type="ref"}

In spite of the aforementioned sporadic clinical observations favouring PTX in dialysis patients, large scaled studies investigating the changes in the risk of ACS in dialysis patients who underwent PTX are scant. The objective of the present study was to investigate the risk of incident ACS in these patients in a nationally representative cohort. We hypothesized that dialysis‐dependent ESRD patients with severe SHPT who have undergone PTX have a reduced risk of ACS.

METHODS {#nep12958-sec-0008}
=======

Data source {#nep12958-sec-0009}
-----------

Taiwan\'s National Health Insurance (NHI) programme, which was established in 1995, offers comprehensive, universal health insurance coverage for all residents of Taiwan and covered more than 99.9% of the population in 2014.[16](#nep12958-bib-0016){ref-type="ref"} The National Health Insurance Research Database (NHIRD) is managed, maintained, and released by Taiwan\'s National Health Research Institutes (NHRI). To protect individual privacy, patients\' data are encrypted. In this study, we used the Registry for Catastrophic Illness Patient Database (RCIPD), which is a subset of the NHIRD. The RCIPD contains medical claims data from the insured suffering from any of the 30 categories of major diseases (e.g., cancer, chronic mental illness, ESRD, and autoimmune diseases) requiring long‐term care. The entitlement of the registry for catastrophic illness exempts patients from the healthcare copayment.[17](#nep12958-bib-0017){ref-type="ref"} The NHIRD contains patient information, such as demographic data, all records of clinical visits and hospitalization, prescribed drugs and dosages, and disease diagnoses. Diseases were coded based on the International Classification of Disease Diagnoses, Ninth Revision, of Clinical Modification (ICD‐9‐CM).

Ethics statement {#nep12958-sec-0010}
----------------

The NHIRD encrypts patient personal information to protect privacy and provides researchers with anonymous identification numbers associated with relevant claims information, including sex, date of birth, medical services received, and prescriptions. Therefore, patient consent is not required to access the NHIRD. This study was approved to fulfil the condition for exemption by the Institutional Review Board (IRB) of China Medical University (CMUH‐104‐REC2--115). The IRB also specifically waived the consent requirement.

Study population {#nep12958-sec-0011}
----------------

Figure [1](#nep12958-fig-0001){ref-type="fig"} illustrates the study framework. We enrolled patients aged ≥18 years, diagnosed with ESRD (defined as those who had catastrophic illness registration cards for ESRD, ICD‐9‐CM 585), and received long‐term renal replacement therapy (i.e., dialysis or renal transplant) for more than 90 days during 2000--2007. We conducted a population‐based retrospective cohort study in which we assigned patients with ESRD who underwent PTX (ICD‐9 codes for procedure 06.8) for the first time during 2000--2008 to the PTX group. The date of the first PTX was considered the index date. We identified the non‐PTX group by propensity score (PS) matching. We applied a multivariate logistic regression model for the probability of receiving PTX for the PTX group.[18](#nep12958-bib-0018){ref-type="ref"} We incorporated sex, age, insured amount, urbanization, diabetes, HL, HTN, atrial fibrillation (AF), CHF, stroke, chronic obstructive pulmonary disease (COPD), obesity, alcohol‐related disease, years since ESRD diagnosis, and year of index date in the PS model. The exclusion criteria for both groups included ACS (ICD‐9‐CM 410, 411.1, and 411.8), renal transplantation (ICD‐9‐CM V42.0 and 996.81), parathyroid tumour (ICD‐9 CM 194.1 and 227.1), or a parathyroid disorder (ICD‐9 CM code 252.8) before the index date or missing information on sex or age.

![Flowchart of the recruitment procedure.ACS, acute coronary syndrome; ESRD, end stage renal disease; PTX, parathyroidectomy.](NEP-23-139-g001){#nep12958-fig-0001}

Covariates and outcomes {#nep12958-sec-0012}
-----------------------

Demographic factors included sex, age (groups aged 18--34, 35--49, 50--64, and ≥65 years), premium‐based income, and urbanization. Premium‐based income was classified into three levels: \<15 000, 15 000--29 999, and ≥30 000 (NT\$/month). City districts and townships where patients registered for insurance were grouped into four urbanization levels according to the population density (people/km^2^), ratio of people whose education level is a college degree or higher, ratio of people aged older than 65 years, ratio of agricultural workers, and the number of physicians per 100 000 persons.[19](#nep12958-bib-0019){ref-type="ref"} Level 1 indicates the most urbanized area, and level 4 represents the least urbanized area. Considering the fact that over 90% of patients with ESRD in Taiwan received haemodialysis,[20](#nep12958-bib-0020){ref-type="ref"} we did not include dialysis modality (haemodialysis versus peritoneal dialysis) in the adjustment variables.

Comorbidity records were determined for each patient before the index date. The records included DM (ICD‐9‐CM 250), HL (ICD‐9‐CM 272.0--272.4), HTN (ICD‐9‐CM 401--405), AF (ICD‐9‐CM 427.31), CHF (ICD‐9‐CM 398.91, 425, and 428), stroke (ICD‐9‐CM 430--438), COPD (ICD‐9‐CM 491--494 and 496), obesity (ICD‐9‐CM 278), and alcohol‐related diseases (ICD‐9‐CM 291, 303, 305, 571.0, 571.1, 571.2, 571.3, 790.3, and V11.3).

The definition of ACS included ST‐elevation and Non‐ST elevation myocardial infarction but not unstable angina. The recorded outcome was ACS (ICD‐9‐CM 410, 411.1, and 411.8). Both groups were followed from the index date to the first diagnosis date of ACS, withdrawal from the NHI program, or the end of 2011, whichever occurred first.

Statistical analyses {#nep12958-sec-0013}
--------------------

Continuous variables were expressed as means and standard deviation (SD), whereas categorical variables were expressed as numbers and percentages. We used Student\'s *t*‐test and Pearson\'s ^2^ test for continuous and categorical variables, respectively, for comparing the differences between the PTX and non‐PTX groups in terms of sex, age, premium‐based income, urbanization, and comorbidities. The incidence density rate (per 1000 person‐years) of ACS was calculated as the incidence of ACS during follow‐up divided by person‐years at risk for each group according to sex, age, and comorbidities. Multivariable Cox proportional hazards regression models were used to assess the risk of ACS. The covariates adjusted in the multivariable models included sex, age, premium‐based income, urbanization, diabetes, HL, HTN, AF, CHF, stroke, COPD, obesity, alcohol‐related disease, year of ESRD diagnosis, and year of index date. We also evaluated the association of PTX on the risk of ACS in various subgroups according to sex, age, comorbidities, and the follow‐up period. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for quantifying the ACS risk. The interactions of PTX with sex, age, diabetes, HL, HTN, AF, CHF, stroke, COPD, obesity, and alcohol‐related disease were further examined by adding their product terms into the full model and the likelihood ratio test was used to test its significance. *P* \< 0.05 was considered significant for 2‐sided tests. All analyses were performed using SAS Version 9.4 (SAS Institute Inc., Cary, NC, USA).

RESULTS {#nep12958-sec-0014}
=======

In all, we have 1047 patients in the PTX group and 4188 patients in the non‐PTX group (Table [1](#nep12958-tbl-0001){ref-type="table-wrap"}). Both groups had similar distributions of sex, age, insured amount, urbanization, diabetes, HL, HTN, AF, CHF, stroke, COPD, obesity and alcohol‐related disease. Women dominated the study groups (65.2%) and about 84.9% of patients were younger than 64 years old. The mean ages of the non‐PTX and PTX groups were 53.6 (SD = 12.8) and 52.1 (SD = 11.8) years, respectively.

###### 

Demographic factors and comorbidity of patients with end stage renal disease according to parathyroidectomy (PTX) status

                                  Before PS matching   After PS matching                                                                      
  ------------------------------ -------------------- ------------------- ------ --------------- ------------ ------ -------- ------ -------- -----------
                                    Non‐PTX group          PTX group              Non‐PTX group   PTX group                                   
                                     *n* = 55917         *N n* = 1335              *n* = 4188     *n* = 1047                                  
  Variables                              *n*                  \%           *n*         \%         *P*‐value    *n*      \%     *n*      \%     *P*‐value
  Year of ESRD diagnosis                                                                           \<0.001                                       0.96
  2000                                   6006                10.7          331        24.8                     785     18.7    214     20.4   
  2001                                   6271                11.2          298        23.3                     797     19.0    199     19.0   
  2002                                   6619                 1.8          200        15.0                     722     17.2    174     16.6   
  2003                                   6847                12.2          207        15.5                     763     18.2    186     17.8   
  2004                                   6959                12.5          131        9.81                     478     11.4    118     11.3   
  2005                                   7574                13.6           84        6.29                     330     7.88     79     7.55   
  2006                                   7517                13.4           58        4.34                     206     4.92     53     5.06   
  2007                                   8124                14.5           26        1.95                     107     2.55     24     2.29   
  Year of index date                                                                               \<0.001                                       0.99
  2000                                   1477                2.64           2         0.15                      10     0.24     2      0.19   
  2001                                   3135                5.61           17        1.27                      58     1.38     14     1.34   
  2002                                   4051                7.24           17        1.27                      52     1.24     15     1.43   
  2003                                   4972                8.89           44        3.30                     153     3.65     40     3.82   
  2004                                   5903                10.6           93        6.97                     322     7.69     84     8.02   
  2005                                   6848                12.3          180        13.5                     618     14.8    158     15.1   
  2006                                   8192                14.7          281        21.1                     857     20.5    217     20.7   
  2007                                  10463                18.7          317        23.8                     970     23.2    241     23.0   
  2008                                  10876                19.5          384        28.8                     1148    27.4    276     26.4   
  Sex                                                                                              \<0.001                                       0.95
  Women                                 28634                51.2          907        67.9                     2739    65.4    683     65.2   
  Men                                   27283                48.8          428        32.1                     1449    34.6    364     34.8   
  Age at receiving PTX, years                                                                      \<0.001                                       0.74
  18--34                                 2032                3.63          123        9.21                     349     8.33     87     8.31   
  35--49                                 8286                14.8          455        34.1                     1259    30.1    333     31.8   
  50--64                                18565                33.2          589        44.1                     1934    46.2    469     44.8   
  ≥65                                   27034                48.4          168        12.6                     646     15.4    158     15.1   
  Mean (SD)                              62.9               (14.1)         51.3      (11.6)        \<0.001     53.6   (12.8)   52.1   (11.8)   \< 0.001
  Insured amount (NT\$/ month)                                                                     \<0.001                                       0.74
  \< 15 000                             32448                58.0          595        44.6                     1954    46.7    481     45.9   
  15 000--29999                         19564                35.0          534        40.0                     1664    39.7    414     39.5   
  ≥ 30 000                               3905                6.98          206        15.4                     570     13.6    152     14.5   
  Urbanization                                                                                     \<0.001                                       0.84
  Level 1 (highest)                     14414                25.8          346        25.9                     1045    25.0    270     25.8   
  Level 2                               16584                30.0          416        31.2                     1329    31.7    339     32.4   
  Level 3                                9481                17.0          285        21.4                     869     20.8    207     19.8   
  Level 4 (lowest)                      15438                27.6          288        21.6                     945     22.6    231     22.1   
  Comorbidity                                                                                                                                 
  Diabetes                              28744                51.4          245        18.4         \<0.001     875     20.9    225     21.5      0.70
  Hyperlipidemia                        27815                49.7          652        48.8           0.53      2052    49.0    508     48.5      0.81
  Hypertension                          52040                93.1          1248       93.5           0.59      3886    92.8    970     92.7      0.93
  AF                                     2562                4.58           27        2.02         \<0.001      93     2.22     24     2.29      0.98
  CHF                                   19919                35.6          336        25.2         \<0.001     1009    24.1    276     26.4      0.14
  Stroke                                11277                20.2           79        5.92         \<0.001     236     5.64     71     6.78      0.18
  COPD                                  14719                26.3          209        15.7         \<0.001     680     16.2    182     17.4      0.40
  Obesity                                429                 0.77           21        1.57          0.002       47     1.12     17     1.62      0.24
  Alcohol‐related disease                1582                2.83           16        1.20         \<0.001      43     1.03     15     1.43      0.34

AF, atrial fibrillation; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; SD, standard deviation.

During an average follow‐up of 4.16 years, 69 and 303 patients from the PTX and non‐PTX groups, respectively, developed ACS. The incidence density rates of ACS were 14.2 and 17.9 per 1000 person‐years for the PTX and non‐PTX groups, respectively. After adjustments for sex, age, premium‐based income, urbanization of residency, comorbidities, year of ESRD diagnosis, and year of index date, the PTX group demonstrated a significantly lower risk of ACS than did the non‐PTX group (adjusted HR \[aHR\] = 0.74, 95% CI = 0.57--0.96). Several traditional cardiovascular risk factors such as diabetes, HL, CHF, stroke and obesity appeared to be strong predictors of ACS (Table [2](#nep12958-tbl-0002){ref-type="table-wrap"}).

###### 

Cox model measured hazard ratios and 95% confidence interval of acute coronary syndrome (ACS) associated with parathyroidectomy (PTX) and covariates

  Variables                      Event no.   Person‐years   IR                              HR^†^ (95% CI)
  ------------------------------ ----------- -------------- ------ -----------------------------------------------------------------
  Year of ESRD diagnosis                                           
  2000                           101         4474           22.6                           1.32 (0.59--2.93)
  2001                           68          4561           14.9                           0.99 (0.44--2.20)
  2002                           50          3699           13.5                           0.84 (0.37--1.89)
  2003                           63          3880           16.2                           1.04 (0.47--2.31)
  2004                           37          2321           15.9                           0.98 (0.43--2.22)
  2005                           29          1536           18.9                           1.19 (0.52--2.74)
  2006                           17          884            19.2                           1.06 (0.44--2.59)
  2007                           7           418            16.7                                 1.00
  Year of index date                                               
  2000                           2           34             58.3                           1.74 (0.41--7.38)
  2001                           8           394            20.3                           1.26 (0.57--2.78)
  2002                           6           403            14.9                           0.70 (0.29--1.71)
  2003                           19          990            19.2                           1.11 (0.63--1.94)
  2004                           24          2230           10.8                           0.62 (0.37--1.01)
  2005                           66          3886           17.0                           1.02 (0.71--1.45)
  2006                           75          4812           15.6                           0.80 (0.58--1.12)
  2007                           88          4608           19.1                           1.05 (0.77--1.43)
  2008                           84          4418           19.0                                 1.00
  PTX                                                              
  No                             303         16926          17.9                                 1.00
  Yes                            69          4848           14.2      0.74 (0.57--0.96)[*\**](#nep12958-note-0005){ref-type="fn"}
  Sex                                                              
  Women                          219         14422          15.2                                 1.00
  Men                            153         7353           20.8    1.53 (1.24--1.90)[*\*\*\**](#nep12958-note-0007){ref-type="fn"}
  Age, years                                                       
  18--34                         13          2087           6.23                                 1.00
  35--49                         86          7392           11.6      1.96 (1.09--3.53)[*\**](#nep12958-note-0005){ref-type="fn"}
  50‐64                          206         9717           21.2    2.75 (1.55--4.87)[*\*\*\**](#nep12958-note-0007){ref-type="fn"}
  ≥65                            67          2579           26.0    2.92 (1.58--5.39)[*\*\*\**](#nep12958-note-0007){ref-type="fn"}
  Insured amount (NT\$/ month)                                     
  \<15000                        197         9658           20.4                                 1.00
  15 000--29 999                 140         8701           16.1                           0.95 (0.76--1.20)
  ≥30 000                        35          3416           10.2     0.57 (0.40--0.83)[*\*\**](#nep12958-note-0006){ref-type="fn"}
  Urbanization                                                     
  Level 1 (highest)              85          5658           15.0                                 1.00
  Level 2                        120         6918           17.4                           1.15 (0.87--1.53)
  Level 3                        73          4409           16.6                           1.09 (0.79--1.49)
  Level 4 (lowest)               94          4790           19.6                           1.20 (0.89--1.62)
  Comorbidity                                                      
  Diabetes                                                         
  No                             233         18015          12.9                                 1.00
  Yes                            139         3759           37.0    1.92 (1.53--2.41)[*\*\*\**](#nep12958-note-0007){ref-type="fn"}
  Hyperlipidaemia                                                  
  No                             136         11691          11.6                                 1.00
  Yes                            236         10083          23.4    1.52 (1.21--1.91)[*\*\*\**](#nep12958-note-0007){ref-type="fn"}
  Hypertension                                                     
  No                             11          1824           6.03                                 1.00
  Yes                            361         19950          18.1                           1.82 (0.99--3.35)
  AF                                                               
  No                             359         21415          16.8                                 1.00
  Yes                            13          360            36.1                           1.61 (0.92--2.82)
  CHF                                                              
  No                             235         16973          13.9                                 1.00
  Yes                            137         4802           28.5    1.66 (1.33--2.06)[*\*\*\**](#nep12958-note-0007){ref-type="fn"}
  Stroke                                                           
  No                             337         20782          16.2                                 1.00
  Yes                            35          993            35.3      1.45 (1.01--2.07)[*\**](#nep12958-note-0005){ref-type="fn"}
  COPD                                                             
  No                             293         18601          15.8                                 1.00
  Yes                            79          3174           24.9                           1.18 (0.92--1.53)
  Obesity                                                          
  No                             362         21538          16.8                                 1.00
  Yes                            10          237            42.2      2.21 (1.16--4.21)[*\**](#nep12958-note-0005){ref-type="fn"}
  Alcohol‐related disease                                          
  No                             369         21540          17.1                                 1.00
  Yes                            3           235            12.8                           0.69 (0.22--2.16)

AF, atrial fibrillation; CHF, congestive heart failure; CI, confidence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; IR, incidence density rate, per 1,000 person‐years; PTX, parathyroidectomy.

Multivariable analysis including year of end‐stage renal disease (ESRD) diagnosis, year of index date, PTX, sex, age(categorical), insured amount, urbanization, diabetes, hyperlipidaemia, hypertension, atrial fibrillation, congestive heart failure, stroke, chronic obstructive pulmonary disease, obesity, and alcohol‐related disease.

*P* \< 0.05,

*P* \< 0.01,

*P* \< 0.001.

Table [3](#nep12958-tbl-0003){ref-type="table-wrap"} and Figure [2](#nep12958-fig-0002){ref-type="fig"} showed risk of ACS for PTX and non‐PTX group by stratification of age, sex, comorbidities and follow‐up period. Age stratification showed that the PTX group were associated with reduced risk of ACS compared with the non‐PTX in the age group of 18--64 years (aHR = 0.73, 95% CI = 0.54--0.98). In participants with CHF and with stroke, the PTX group had reduced risk of ACS than did the non‐PTX group (aHR = 0.64, 95% CI = 0.42--0.99 for those with CHF; and aHR = 0.31, 95% CI = 0.10--0.94 for those with stroke). Similarly, in participants without obesity and without alcohol‐related disease, the PTX group had lower risk of ACS than did the non‐PTX group (aHR = 0.75, 95% CI = 0.57--0.98 for those without obesity; and aHR = 0.77, 95% CI = 0.59--0.99 for those without alcohol‐related disease; Fig. [2](#nep12958-fig-0002){ref-type="fig"}). In addition, the PTX group was associated with a null risk of ACS than in the non‐PTX group in all groups of follow‐up period (Table [3](#nep12958-tbl-0003){ref-type="table-wrap"}).

###### 

Incidence density rates and hazard ratios of acute coronary syndrome (ACS) according to parathyroidectomy (PTX) status stratified by follow‐up period.

                             Non‐ PTX group    PTX group     Compared to non‐PTX group                                    
  ------------------------- ---------------- -------------- --------------------------- ----------- -------------- ------ ----------------------------------------------------
  Follow‐up period, years      Event no.      Person‐years              IR               Event no.   Person‐years    IR    HR[†](#nep12958-note-0009){ref-type="fn"} (95% CI)
  ≤ 2                             139             7529                 18.5                 29           2008       14.4                   0.77 (0.52--1.16)
  2--4                             99             5930                 16.7                 24           1712       14.0                   0.80 (0.51--1.25)
  4--6                             52             2683                 19.4                 10           837        11.9                   0.58 (0.29--1.15)
  \> 6                             13             785                  16.6                  6           291        20.6                   1.12 (0.39--3.22)

CI, confidence interval; HR, hazard ratio; IR, incidence density rate, per 1,000 person‐years.

Adjusting for sex, age (continuous), premium‐based income, urbanization, diabetes, hyperlipidaemia, hypertension, atrial fibrillation, congestive heart failure, stroke, chronic obstructive pulmonary disease, obesity, alcohol‐related disease, year of end‐stage renal disease (ESRD) diagnosis, and year of index date.

![Risk of ACS according to PTX status stratified by sex, age, and each comorbidity.HR, hazard ratio; CI, confidence interval.† Mutually adjusted for sex, age (continuous), premium‐based income, urbanization, diabetes, hyperlipidaemia, hypertension, atrial fibrillation, congestive heart failure, stroke, chronic obstructive pulmonary disease, obesity, alcohol‐related disease, year of ESRD diagnosis, and year of index date.\* *P* \< 0.05.](NEP-23-139-g002){#nep12958-fig-0002}

DISCUSSION {#nep12958-sec-0015}
==========

In this retrospective nationwide cohort study, we observed that Taiwanese patients with ESRD who had undergone PTX had a 25% lower risk of ACS after adjustments for sex, age, premium‐based income, urbanization, and comorbidities (DM, HTN, HL, AF, CHF, stroke, COPD, obesity, and alcohol‐related diseases). The significant results persisted in the competing risk analysis model. Traditional CV risk factors such as male gender, increasing age, DM, HL, CHF, stroke and obesity were significantly associated with higher risk of ACS. Conversely, a premium‐based income of NT\$ 30 000 or more was a protective factor against the development of ACS. Subgroup analysis showed PTX was associated with reduced risk of ACS in dialysis patients with age under 65, with stroke, without obesity and without alcohol‐related disease.

No study has focused on the association of PTX with ACS in patients with ESRD, though certain research reported a reduced overall CV risk after PTX,[15](#nep12958-bib-0015){ref-type="ref"} supporting our findings. The ACS incidence was 29 per 1000 person‐years according to the data of Wave II of the USRDS Dialysis Morbidity and Mortality study.[21](#nep12958-bib-0021){ref-type="ref"} In our study, the ACS incidence was 17.9 and 14.2 per 1000 person‐years for the non‐PTX and PTX groups, respectively. Cardiac arrest and in‐hospital deaths of dialysis patients were approximately twice higher than those of non‐dialysis patients with AMI.[22](#nep12958-bib-0022){ref-type="ref"} A recent large Japanese registry study also used propensity score match method to compare mortality between PTX and non‐PTX patients undergoing dialysis, and reported lower cardiovascular mortality in PTX group.[23](#nep12958-bib-0023){ref-type="ref"} Our observation is unequivocal because ESRD itself is a well‐accepted high‐CV‐risk condition.

Parathyroidectomy might decrease the incidence density of ACS in dialysis patients by the following mechanisms: first, HD patients with SHPT who underwent PTX demonstrated an improved left and right ventricular ejection fraction and reduced intradialytic hypotension[24](#nep12958-bib-0024){ref-type="ref"} and might further reduce the ACS incidence; while intradialytic hypotension has been a known risk factor for mortality for patients on HD.[25](#nep12958-bib-0025){ref-type="ref"} Second, SHPT has been reported to accelerate atherosclerosis, particularly to enhance coronary calcification through increased insulin resistance, vascular smooth muscle cells proliferation, calcium--phosphorus deposition in vessel walls, and altered lipoprotein metabolism.[26](#nep12958-bib-0026){ref-type="ref"} For patients with ESRD, calcium deposition occurs in both the intimal and medial layers or in the medial layer alone. London *et al*.[6](#nep12958-bib-0006){ref-type="ref"} reported that medial layer calcification increases the risk of mortality. PTX decreases the calcium score of the coronary artery[27](#nep12958-bib-0027){ref-type="ref"} and improves ACS risk factors including blood pressure, total cholesterol, and low‐density lipoprotein cholesterol in kidney transplant recipients.[28](#nep12958-bib-0028){ref-type="ref"} Third, platelet activity and thrombosis also play critical roles in the development of ACS[7](#nep12958-bib-0007){ref-type="ref"}; a previous study reported that the blood level of platelet‐activating factor decreased after PTX in HD patients.[29](#nep12958-bib-0029){ref-type="ref"} Fourth, cardiac autonomic dysfunction, manifested by low indices of heart rate variability, was observed in patients with ACS and predicted future coronary events in patients with a history of MI.[8](#nep12958-bib-0008){ref-type="ref"} Patients with ESRD who underwent PTX exhibited improved heart rate variability.[30](#nep12958-bib-0030){ref-type="ref"} Our findings are consistent with the aforementioned studies.

Our study results have several important clinical implications. First, the risk of ACS decreased significantly in the PTX group only in patients with age under 65, with stroke, without obesity and without alcohol‐related disease. No significant reduction of ACS was observed in patients with other traditional risk factors such as DM, HTN and HL. This implied that, first, traditional CV risk factors were still strong predictors of events in dialysis patients; second, in addition to traditional CV risk factors, there might be other complicated pathogenetic factors of ACS in ESRD, such as atherosclerosis, vascular calcification, and bone‐mineral disease. Further studies are needed to confirm this hypothesis. Second, preventing ACS in dialysis patients is challenging. Although hyperparathyroidism is correlated with a high overall CV risk,[9](#nep12958-bib-0009){ref-type="ref"} little research addressed the direct relationship of ACS risk reduction in patients with ESRD. Our findings provided valuable evidence. However, we had no intention to promote PTX for patients with ESRD with SHPT; but would like to emphasize the importance of controlling SHPT to avoid ominous CV outcomes. Third, the effective treatments to reduce the ACS risk in non‐dialysis patients, including antiplatelet agents, statins, and beta‐blockers, were found ineffective for patients with ESRD.[20](#nep12958-bib-0020){ref-type="ref"}, [31](#nep12958-bib-0031){ref-type="ref"} We reported previously that PTX might reduce the risk of stroke and recommended that hyperparathyroidism be considered as a new CV risk factor for dialysis patients[14](#nep12958-bib-0014){ref-type="ref"}; the present findings support this recommendation. Additional randomized controlled studies are needed to evaluate the effects of PTX and medical treatments on CV risk in dialysis patients complicated with SHPT.

This study has several limitations. First, this study was a secondary data analysis of a health insurance claims database, which lacks information on several crucial CV risk factors such as smoking, body mass index, alcohol use, physical activity, and dietary habits. Nevertheless, we used alcohol‐related diseases as a proxy to adjust for the effect of alcohol intake. We adjusted for the potential confounding effect of body mass index by including HTN, DM, and HL in multivariable models. Moreover, the potential confounding effect of smoking was adjusted by including smoking‐related diseases, namely stroke and COPD. Modification under these restrictions has been accepted previously,[14](#nep12958-bib-0014){ref-type="ref"} though, markers of nutritional status such as serum albumin and creatinine levels (as a marker for muscle volume) were also unavailable. Multivariate analysis with adjustment of several chronic diseases could not completely compensate this limitation. Second, limited by the characteristics of the NHIRD, we have no access to any laboratory data including the levels of PTH, calcium, phosphate, nor calcium‐phosphate products. Besides, the treatment records of vitamin D analogue or calcimimetics treatment had been unavailable because they were either included in the bundled HD payment package or self‐paid. However, the NHI strictly reviews the reimbursement of surgical claims. With approved NHI reimbursements for PTX in ESRD patients on maintenance dialysis (either HD or PD), we believe the PTX group represent ESRD patients with severe SHPT indicated for the operation. Third, there might be significant indication bias in receiving PTX. Chuang *et al*. reported higher rates of PTX were noted in women, younger patients, and in patients without history of DM or HTN.[32](#nep12958-bib-0032){ref-type="ref"} We conducted PS matches to minimize the bias. Patients with ESRD without SHPT might also be included in the non‐PTX group. A recent study by Ho et at.[33](#nep12958-bib-0033){ref-type="ref"} included radionuclide parathyroid scanning as the enrolling criteria for patients with SHPT and reported reduced mortality in ESRD patients who received PTX, which increased the specificity of the enrolees; however, the exclusion percentage seemed high.

In conclusion, in this nationwide cohort study, we found that PTX is associated with reduced risk of ACS in dialysis patients after adjustment for comorbidities. Further prospective randomized studies are needed to delineate the relationship between PTX and the changes of the risk of ACS.
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